Sponsor has elected to place the Tapestry RC PMCF study on hold. The Tapestry RC product line is being enhanced, and we have chosen to delay data collection on this product until the new devices are available. Study is anticipated to resume in 2026.

The study design is a prospective, multi-center, single-arm, non-randomized, and noncontrolled post market clinical follow-up study involving orthopedic surgeons skilled in arthroscopic rotator cuff repair as determined by the Sponsor.

The objectives of the study are to calculate the overall clinical success rate, the performance, and clinical benefits, and confirm the safety of the Tapestry RC Biointegrative Implant System.

• The clinical success will be evaluated by absence of rotator cuff re-tear.
• The performance and clinical benefits will be evaluated by functional outcomes measured using standard scoring systems such as the American Shoulder and Elbow Surgeons Shoulder Score (ASES), Visual Analogue Scale (VAS), Constant-Murley Score (CMS), Single Assessment Numeric Evaluation (SANE), Return to Activity, Patient Satisfaction, EQ-5D-5L, and rotator cuff repair outcomes measured using MRI evaluation for repair integrity, quality, tendon tissue thickness and regeneration.
• The safety of the Tapestry RC Biointegrative Implant System will be assessed by monitoring the frequency and incidence of adverse events.

The primary endpoint of this study is defined by the rotator cuff re-tear rate post-operatively. This will be measured against the success criteria of the re-tear rate in 18.3% of cases at two years.

Inclusion Criteria:

1. Adult, 21 years and older;

2. Patient with a diagnosis of a symptomatic primary partial-thickness or full-thickness tear of the supraspinatus and/or infraspinatus tendons amenable to repair that meets one of the following criteria:

   • Partial-thickness tear planned for standalone treatment (no surgical repair with sutures/suture anchors) with the Tapestry Biointegrative Implant, or
   • Full-thickness tear planned for treatment with the Tapestry Biointegrative Implant as an adjunct to surgical repair (single or double row repair with sutures/suture anchors);

3. Patient is able and willing to complete the protocol required follow-up;

4. Patient is able and willing to sign the IRB approved informed consent;

5. Independent of study participation, patient qualifies for arthroscopic rotator cuff repair and meets the approved indications for use of the commercially available Tapestry RC Biointegrative Implant System

Exclusion Criteria:

1. Hypersensitivity to bovine-derived materials or poly(D,L-lactide) materials;
2. Patient with an irreparable or partially reparable rotator cuff tear;
3. Revision rotator cuff repair;
4. Off-label use of the study device;
5. Patient is known to be pregnant or nursing;
6. Patient is a prisoner;
7. Patient is a known alcohol or drug abuser;
8. Patient has a psychiatric illness, neurologic disorder, or cognitive deficit that will not allow for proper informed consent or compliance with study requirements;
9. Patient is unable to tolerate magnetic resonance imaging (MRI), due to psychiatric or medical contraindications;
10. Patient is unwilling or unable to give consent or to comply with the follow-up program;
11. Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.

The study population will include both males and females undergoing arthroscopic rotator cuff repair due to partial or full-thickness tears of the supraspinatus and/or infraspinatus tendon.